Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases

British Journal of Surgery

Volumn 97, Issue 4, 2010, Pages 537-543

  Cao, C Q ^a   Yan, T D ^a   Bester, L ^b   Liauw, W ^b   Morris, D L ^a  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 77949347750     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6931     Document Type: Article

References (37)

1. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445.
2. Sutcliffe R, Maguire D, Ramage J, Rela. M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg 2004; 187: 39-46.
3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumours. Cancer 2003; 97: 934-959.
4. Oberg K. Neuroendocrine gastrointestinal tumours - a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10(Suppl 2):S3-S8.
5. Veenendaal LM, Borel Rinkes IH, Lips CJ, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 2006; 4: 35.
6. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumours. Surgery 1990; 108: 1091-1096.
7. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995; 19: 76-82.
8. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumours. Surg Oncol Clin N Am 2003; 12: 231-242.
9. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36-42.
10. Norton JA. Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005; 19: 577-583.
11. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumours. Ann Surg Oncol 2006; 13: 572-581.
12. Le Treut YP, Grégoire E, Belghiti J, Boulot O, Soubrane O, Mantion G et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumours: an 85-case French multicentric report, Am J Transplant 2008; 8: 1205-1213.
13. Knigge U, Hansen CP, Stadil F. Interventional treatment of neuroendocrine liver metastases. Surgeon 2008; 6: 232-239.
14. Osborne D, Zervos E, Strosberg J, Boe BA, Malafa M, Rosemurgy AS et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumours. Ann Surg Oncol 2006; 13: 572-581.
15. Gupta S, Johnson M, Murthy R, Ahrar K, Wallace MJ, Madoff DC et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104: 1590-1602.
16. Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumours. Cancer 1998; 83: 2293-2301.
17. Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006; 13: 72-78.
18. O'Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80(Suppl 1): 79-84.
19. Di Bartolomeo M, Bajetta. E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V et al. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol 1995; 6: 77-79.
20. Välimäki M, Järvinen H, Salmela P, Sane T, Sjöblom SM, Pelkonen R. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991; 67: 547-549.
21. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-438.
22. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
23. 90Y microspheres (TheraSphere): safety, tumour response, and survival. J Vasc Intern Radiol 2005; 16: 1627-1639.
24. Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005; 16: 937-945.
25. 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience, Int J Radiat Oncol Biol Phys 2006; 65: 412-425.
26. 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 27'1-279.
27. 90Y radioembolization for metastatic neuroendocrine liver tumours: preliminary results from a multi-institutional experience. Ann Surg 2008; 247: 1029-1035.
28. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921-929.
29. 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and mediodologic considerations. J Vasc Interv Radiol 2006; 17: 1251-1278.
30. 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vase Interv Radiol 2006; 17: 1425-1439.
31. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3 : comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17: 1571-1593.
32. Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vase Interv Radiol 2008; 19: 145-151.
33. 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2001; 30: 571-592.
34. Bester L, Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vase Interv Radiol 2007; 18: 1310-1314.
35. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13 -23.
36. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
37. Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumours: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008; 19: 282-288.